About Event

Welcome to the 4^th RNAi-Based Therapeutics Summit

2022 has been an exciting year for the RNAi field with Alnylam getting both EMA and FDA approval of AMVUTTRA^TM, Atalanta Therapeutics launching with $110m, Siranomics dosing the first patient with STP705, Arrowhead enrolling their first patient evaluating HZN-457, RNAi therapeutics have reached an inflection point in 2023.

For the very first time, we have seen the release of FDA guidance on clinical pharmacology considerations offering some guidance for drug developers to advance their pipelines.

Despite this, targeted delivery, process development, selectivity, and limited half-life remain big challenges to overcome so the 3-day jam-packed agenda at the 4^th RNAi-Based Therapeutics Summit returned to unite 90+ trailblazers, pioneers, and new entrants to turbocharge RNAi drug development.

After listening to your feedback in 2022 and researching with industry leaders, the 2023 conference covered:

	Deep dive into delivery mechanisms, including lipid conjugates, that are targeting the skin, eyes, and CNS that is expanding the therapeutic target space for siRNA therapies with, Eli Lilly & Altamira Therapeutics
	Hear key clinical updates of siRNA candidates tackling oncology indications as well as new targets that are being explored with Siranomics
	Uncover computational modeling approaches to enhance target identification, improve biological understanding, and fast-track siRNA discovery with e-Therapeutics & Tallas Biotech
	Revealing next-generation dual targeting siRNAs with improved tolerability and efficacy for robust silencing in the brain with University of Massachusetts & Argonaute RNA
	Learn about the strategies for successful scale-up and ways to tackle quick turnaround times to meet the demands for in-person trials whilst ensuring robust production processes with Olix Pharmaceuticals